{ "version": "2.2", "instance": { "antx-20231231.htm": { "nsprefix": "antx", "nsuri": "http://www.an2therapeutics.com/20231231", "dts": { "inline": { "local": [ "antx-20231231.htm" ] }, "schema": { "local": [ "antx-20231231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd" ] } }, "keyStandard": 37, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2023": 3 }, "contextCount": 3, "entityCount": 1, "segmentCount": 0, "elementCount": 517, "unitCount": 2, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 38 }, "report": { "R1": { "role": "http://www.an2therapeutics.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_9f0a7b9f-1405-4e9a-8300-07aae1a7e8a6", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "antx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9f0a7b9f-1405-4e9a-8300-07aae1a7e8a6", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "antx-20231231.htm", "first": true, "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "antx_AccountingPoliciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "AccountingPoliciesLineItems", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Accounting policies.", "label": "Accounting Policies [Line Items]", "terseLabel": "Accounting Policies [Line Items]" } } }, "auth_ref": [] }, "antx_AccountingPoliciesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "AccountingPoliciesTable", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Accounting policies.", "label": "Accounting Policies [Table]", "terseLabel": "Accounting Policies [Table]" } } }, "auth_ref": [] }, "us-gaap_AccountingStandardsUpdate201602Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingStandardsUpdate201602Member", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Accounting Standards Update 2016-02 [Member]", "terseLabel": "ASU 2016-12" } } }, "auth_ref": [] }, "us-gaap_AccountingStandardsUpdate201613Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingStandardsUpdate201613Member", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Accounting Standards Update 2016-13 [Member]", "terseLabel": "ASU 2016-13" } } }, "auth_ref": [] }, "us-gaap_AccountingStandardsUpdate201811Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingStandardsUpdate201811Member", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Accounting Standards Update 2018-11 [Member]", "terseLabel": "ASU 2018-11" } } }, "auth_ref": [] }, "us-gaap_AccountingStandardsUpdate201815Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingStandardsUpdate201815Member", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Accounting Standards Update 2018-15 [Member]", "terseLabel": "ASU 2018-15" } } }, "auth_ref": [] }, "us-gaap_AccountingStandardsUpdate202110Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingStandardsUpdate202110Member", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Accounting Standards Update 2021-10 [Member]", "terseLabel": "ASU 2021-10" } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Accrued Liabilities, Current", "terseLabel": "Accrued liabilities", "totalLabel": "Total accrued liabilities" } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesCurrentAbstract", "lang": { "en-us": { "role": { "label": "Accrued Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "antx_AccruedOfferingCostsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "AccruedOfferingCostsCurrent", "crdr": "credit", "calculation": { "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Accrued offering costs current.", "label": "Accrued Offering Costs Current", "terseLabel": "Accrued offering costs" } } }, "auth_ref": [] }, "antx_AccruedProfessionalServicesExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "AccruedProfessionalServicesExpenses", "crdr": "credit", "calculation": { "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Accrued professional services expenses", "label": "Accrued Professional Services Expenses", "terseLabel": "Accrued professional services expenses" } } }, "auth_ref": [] }, "antx_AccruedResearchAndDevelopmentRelatedExpensesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "AccruedResearchAndDevelopmentRelatedExpensesCurrent", "crdr": "credit", "calculation": { "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Accrued research and development-related expenses current.", "label": "Accrued Research And Development Related Expenses Current", "terseLabel": "Accrued research and development-related expenses" } } }, "auth_ref": [] }, "antx_AccruedResearchAndDevelopmentRelatedExpensesRelatedPartyCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "AccruedResearchAndDevelopmentRelatedExpensesRelatedPartyCurrent", "crdr": "credit", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Accrued research and development-related expenses- related party.", "label": "Accrued Research And Development Related Expenses Related Party Current", "terseLabel": "Accrued research and development-related expenses- related party" } } }, "auth_ref": [] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": [ "r40" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": [ "r46" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": [ "r46" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": [ "r46" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": [ "r46" ] }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Accounting Standards Update [Axis]" } } }, "auth_ref": [] }, "antx_AdjuvantGlobalHealthAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "AdjuvantGlobalHealthAgreementMember", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Adjuvant global health agreement.", "label": "Adjuvant Global Health Agreement [Member]", "terseLabel": "Adjuvant Global Health Agreement" } } }, "auth_ref": [] }, "antx_AggregateDevelopmentAndRegulatoryMilestonesEligibleToReceive": { "xbrltype": "monetaryItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "AggregateDevelopmentAndRegulatoryMilestonesEligibleToReceive", "crdr": "debit", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Aggregate development and regulatory milestones eligible to receive.", "label": "Aggregate Development and Regulatory Milestones Eligible to Receive", "terseLabel": "Aggregate development and regulatory milestones eligible to receive" } } }, "auth_ref": [] }, "antx_AggregateMaximumPaymentsUponAchievementOfCommercialAndSalesThresholdMilestones": { "xbrltype": "monetaryItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "AggregateMaximumPaymentsUponAchievementOfCommercialAndSalesThresholdMilestones", "crdr": "credit", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Aggregate maximum payments upon achievement of commercial and sales threshold milestones.", "label": "Aggregate Maximum Payments Upon Achievement Of Commercial and Sales Threshold Milestones", "terseLabel": "Aggregate maximum payments upon achievement of commercial and sales threshold milestones" } } }, "auth_ref": [] }, "antx_AggregateMaximumPaymentsUponAchievementOfDevelopmentMilestones": { "xbrltype": "monetaryItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "AggregateMaximumPaymentsUponAchievementOfDevelopmentMilestones", "crdr": "credit", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Aggregate maximum payments upon achievement of development milestones.", "label": "Aggregate Maximum Payments Upon Achievement Of Development Milestones", "terseLabel": "Aggregate maximum payments upon achievement of development milestones" } } }, "auth_ref": [] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r10", "r22", "r32", "r58" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": [ "r13", "r25", "r35", "r61" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": [ "r46" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": [ "r53" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": [ "r17", "r26", "r36", "r53", "r62", "r66", "r74" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": [ "r72" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityIncentivePlanAndStockbasedCompensationAdditionalInformationDetails", "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityIncentivePlanAndStockbasedCompensationSummaryOfTotalStockbasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expense", "terseLabel": "Total stock-based compensation", "verboseLabel": "Share-based payment arrangement expense" } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "antx_AnacorLicensingAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "AnacorLicensingAgreementMember", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Anacor licensing agreement.", "label": "Anacor Licensing Agreement [Member]", "terseLabel": "Anacor Licensing Agreement" } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Anti-dilutive securities excluded from computation of diluted per share" } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]" } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name [Domain]" } } }, "auth_ref": [] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails", "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityAdditionalInformationDetails", "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]" } } }, "auth_ref": [] }, "us-gaap_AssetBackedSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetBackedSecuritiesMember", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsFairValueMeasurementOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset-backed Securities", "label": "Asset-Backed Securities [Member]" } } }, "auth_ref": [] }, "antx_AtTheMarketOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "AtTheMarketOfferingMember", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityAdditionalInformationDetails", "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "At-the-market offering.", "label": "At The Market Offering [Member]", "terseLabel": "At the Market Offering" } } }, "auth_ref": [] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorFirmId", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Firm ID", "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r4", "r5", "r18" ] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorLocation", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Location", "label": "Auditor Location" } } }, "auth_ref": [ "r4", "r5", "r18" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorName", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Name", "label": "Auditor Name" } } }, "auth_ref": [ "r4", "r5", "r18" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "calculation": { "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsFairValueMeasurementOnRecurringBasisDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsFairValueMeasurementOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Unrealized Gain" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "crdr": "debit", "calculation": { "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsFairValueMeasurementOnRecurringBasisDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsFairValueMeasurementOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "negatedLabel": "Unrealized Loss" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "crdr": "debit", "calculation": { "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsFairValueMeasurementOnRecurringBasisDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsFairValueMeasurementOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Amortized Cost", "totalLabel": "Amortized Cost" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "calculation": { "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsFairValueMeasurementOnRecurringBasisDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsFairValueMeasurementOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale", "terseLabel": "Estimated Fair Value", "totalLabel": "Debt Securities, Available-for-sale, Total", "verboseLabel": "Debt securities, available-for-sale investments" } } }, "auth_ref": [] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": [ "r69" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": [ "r70" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": [ "r65" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": [ "r65" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": [ "r65" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": [ "r65" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": [ "r65" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": [ "r65" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityIncentivePlanAndStockbasedCompensationAdditionalInformationDetails", "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquitySharesOfCommonStockReservedForFutureIssuanceDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type" } } }, "auth_ref": [] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": [ "r68" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r67" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": [ "r66" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": [ "r66" ] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationAxis", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Balance Sheet Location [Axis]" } } }, "auth_ref": [] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationDomain", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Balance Sheet Location [Domain]" } } }, "auth_ref": [] }, "us-gaap_BalanceSheetRelatedDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetRelatedDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Balance Sheet Related Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "auth_ref": [] }, "antx_BillAndMelindaGatesFoundationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "BillAndMelindaGatesFoundationMember", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureFundingArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Bill and melinda gates foundation.", "label": "Bill and Melinda Gates Foundation [Member]", "terseLabel": "BMGF Grant" } } }, "auth_ref": [] }, "antx_BillMelindaGatesFoundationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "BillMelindaGatesFoundationMember", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Bill Melinda Gates Foundation [Member]", "label": "Bill Melinda Gates Foundation [Member]", "terseLabel": "BMGF" } } }, "auth_ref": [] }, "antx_BriiBiosciencesAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "BriiBiosciencesAgreementMember", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Brii biosciences agreement.", "label": "Brii Biosciences Agreement [Member]", "terseLabel": "Brii Biosciences Agreement" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationConsiderationTransferred1", "crdr": "credit", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Business Combination, Consideration Transferred", "terseLabel": "Fair value of consideration", "totalLabel": "Business Combination, Consideration Transferred, Total" } } }, "auth_ref": [] }, "us-gaap_CaliforniaFranchiseTaxBoardMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CaliforniaFranchiseTaxBoardMember", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "California", "label": "California Franchise Tax Board [Member]" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, at Carrying Value", "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance", "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance", "terseLabel": "Cash equivalents", "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total", "verboseLabel": "Cash and cash equivalents" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsMember", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsFairValueMeasurementOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Member]", "terseLabel": "Cash and cash Equivalents" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "auth_ref": [] }, "antx_CashCashEquivalentsShortTermInvestmentsAndLongTermInvestment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "CashCashEquivalentsShortTermInvestmentsAndLongTermInvestment", "crdr": "debit", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Cash cash equivalents short term investments and long term investment.", "label": "Cash Cash Equivalents Short Term Investments and Long Term Investment", "terseLabel": "Cash, cash equivalents, short-term investments and long-term investments" } } }, "auth_ref": [] }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": { "xbrltype": "booleanItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Change in Accounting Principle, Accounting Standards Update, Adopted [true false]", "terseLabel": "Change in Accounting Principle, Accounting Standards Update, Adopted [true false]" } } }, "auth_ref": [] }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Change in Accounting Principle, Accounting Standards Update, Adoption Date", "terseLabel": "Change in Accounting Principle, Accounting Standards Update, Adoption Date" } } }, "auth_ref": [] }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect": { "xbrltype": "booleanItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]" } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": [ "r44" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails", "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquitySharesOfCommonStockReservedForFutureIssuanceDetails" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockLineItems", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityAdditionalInformationDetails", "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquitySharesOfCommonStockReservedForFutureIssuanceDetails" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Line Items]" } } }, "auth_ref": [] }, "antx_CloudComputingArrangementsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "CloudComputingArrangementsPolicyTextBlock", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Cloud Computing Arrangements", "label": "Cloud Computing Arrangements [Policy Text Block]", "documentation": "Cloud computing arrangements." } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": [ "r45" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": [ "r45" ] }, "antx_CollaborationAndLicenseAgreementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "CollaborationAndLicenseAgreementsAbstract", "lang": { "en-us": { "role": { "documentation": "Collaboration and license agreements.", "label": "Collaboration And License Agreements [Abstract]" } } }, "auth_ref": [] }, "antx_CollaborationAndLicenseAgreementsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "CollaborationAndLicenseAgreementsLineItems", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Collaboration and license agreements.", "label": "Collaboration And License Agreements [Line Items]", "terseLabel": "Collaboration And License Agreements [Line Items]" } } }, "auth_ref": [] }, "antx_CollaborationAndLicenseAgreementsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "CollaborationAndLicenseAgreementsTable", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Collaboration and license agreements.", "label": "Collaboration And License Agreements [Table]", "terseLabel": "Collaboration And License Agreements [Table]" } } }, "auth_ref": [] }, "antx_CollaborationAndLicenseAgreementsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "CollaborationAndLicenseAgreementsTextBlock", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreements1" ], "lang": { "en-us": { "role": { "documentation": "Collaboration and license agreements.", "label": "Collaboration And License Agreements [Text Block]", "terseLabel": "Collaboration and License Agreements" } } }, "auth_ref": [] }, "us-gaap_CommercialPaperMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommercialPaperMember", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsFairValueMeasurementOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Commercial Paper [Member]", "terseLabel": "Commercial Paper" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingencies1" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "auth_ref": [] }, "antx_CommitmentsAndContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "CommitmentsAndContingenciesLineItems", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Commitments and contingencies.", "label": "Commitments And Contingencies [Line Items]", "terseLabel": "Commitments And Contingencies [Line Items]" } } }, "auth_ref": [] }, "antx_CommitmentsAndContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "CommitmentsAndContingenciesTable", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Commitments and contingencies.", "label": "Commitments And Contingencies [Table]", "terseLabel": "Commitments And Contingencies [Table]" } } }, "auth_ref": [] }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityIncentivePlanAndStockbasedCompensationAdditionalInformationDetails", "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquitySharesOfCommonStockReservedForFutureIssuanceDetails" ], "lang": { "en-us": { "role": { "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Shares of common stock reserved for future issuance (in shares)", "verboseLabel": "Common stock reserved for future issuance (in shares)" } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "auth_ref": [] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value" } } }, "auth_ref": [] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "auth_ref": [] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued", "totalLabel": "Common Stock, Shares, Issued, Total" } } }, "auth_ref": [] }, "us-gaap_CommonStockVotingRights": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockVotingRights", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Common Stock, Voting Rights", "terseLabel": "CommonStockVotingRights" } } }, "auth_ref": [] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": [ "r50" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": [ "r49" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": [ "r51" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": [ "r48" ] }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CompensationAndRetirementDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Retirement Benefits [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Comprehensive Income, Policy [Policy Text Block]", "terseLabel": "Comprehensive Loss" } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskCreditRisk", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentrations of Credit Risk" } } }, "auth_ref": [] }, "antx_ContractTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "ContractTerm", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureFundingArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Contract term.", "label": "Contract Term", "terseLabel": "Contract term" } } }, "auth_ref": [] }, "us-gaap_ConversionOfStockSharesConverted1": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConversionOfStockSharesConverted1", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Conversion of Stock, Shares Converted", "terseLabel": "Shares converted" } } }, "auth_ref": [] }, "us-gaap_CorporateDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CorporateDebtSecuritiesMember", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsFairValueMeasurementOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Corporate Debt Securities", "label": "Corporate Debt Securities [Member]" } } }, "auth_ref": [] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CounterpartyNameAxis", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss", "crdr": "credit", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Total", "periodStartLabel": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Beginning Balance", "periodEndLabel": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Ending Balance", "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss", "terseLabel": "Allowance for credit losses" } } }, "auth_ref": [] }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions", "terseLabel": "Debt securities unrealized loss position, more than12 months number of positions" } } }, "auth_ref": [] }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleUnrealizedGainLoss", "crdr": "credit", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Unrealized Gain (Loss)", "terseLabel": "Net unrealized gain (loss) on available-for-sale investments", "totalLabel": "Debt Securities, Available-for-sale, Unrealized Gain (Loss), Total", "negatedLabel": "Net unrealized gain (loss) on available-for-sale investments" } } }, "auth_ref": [] }, "us-gaap_DeferredChargesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredChargesPolicyTextBlock", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Deferred Charges, Policy [Policy Text Block]", "terseLabel": "Deferred Offering Costs" } } }, "auth_ref": [] }, "us-gaap_DeferredOfferingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredOfferingCosts", "crdr": "debit", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Offering Costs", "terseLabel": "Deferred offering costs" } } }, "auth_ref": [] }, "antx_DeferredTaxAssetsCapitalResearchExpenditures": { "xbrltype": "monetaryItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "DeferredTaxAssetsCapitalResearchExpenditures", "crdr": "debit", "calculation": { "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Deferred tax assets capital research expenditures.", "label": "Deferred Tax Assets Capital Research Expenditures", "terseLabel": "Capital research expenditures" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsGross", "crdr": "debit", "calculation": { "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Gross deferred tax assets", "label": "Deferred Tax Assets, Gross" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsNet", "crdr": "debit", "calculation": { "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net deferred tax assets", "label": "Deferred Tax Assets, Net of Valuation Allowance" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsNetOfValuationAllowanceAbstract", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax assets", "label": "Deferred Tax Assets, Net of Valuation Allowance [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "crdr": "debit", "calculation": { "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net operating loss carryforwards", "label": "Deferred Tax Assets, Operating Loss Carryforwards", "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsOther", "crdr": "debit", "calculation": { "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Deferred Tax Assets, Other" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxCreditCarryforwards", "crdr": "debit", "calculation": { "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax credit carryforwards", "label": "Deferred Tax Assets, Tax Credit Carryforwards", "totalLabel": "Deferred Tax Assets, Tax Credit Carryforwards, Total" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "crdr": "debit", "calculation": { "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost", "terseLabel": "Stock-based compensation" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsValuationAllowance", "crdr": "credit", "calculation": { "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Valuation allowance", "label": "Deferred Tax Assets, Valuation Allowance" } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedContributionPlanAbstract", "lang": { "en-us": { "role": { "label": "Defined Contribution Plan [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount", "crdr": "debit", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Matching contribution." } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedContributionPlanTextBlock", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureDefinedContributionPlan" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Contribution Plan", "label": "Defined Contribution Plan [Text Block]" } } }, "auth_ref": [] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityIncentivePlanAndStockbasedCompensation1" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "Equity Incentive Plan and Stock-Based Compensation" } } }, "auth_ref": [] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r4", "r5", "r18" ] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Financial Statement Error Correction [Flag]", "terseLabel": "Document Financial Statement Error Correction", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r4", "r5", "r18", "r54" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r39" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Documents Incorporated by Reference", "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r2" ] }, "us-gaap_DomesticCountryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DomesticCountryMember", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Federal", "label": "Domestic Tax Authority [Member]" } } }, "auth_ref": [] }, "antx_EarlyExercisedCommonStockSubjectToFutureVestingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "EarlyExercisedCommonStockSubjectToFutureVestingMember", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationDetails" ], "lang": { "en-us": { "role": { "documentation": "Early exercised common stock subject to future vesting.", "label": "Early Exercised Common Stock Subject To Future Vesting [Member]", "terseLabel": "Early Exercised Common Stock Subject to Future Vesting" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureNetLossPerShareSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic", "terseLabel": "Net loss per share attributable to common stockholders, basic", "totalLabel": "Earnings Per Share, Basic, Total" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasicLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasicLineItems", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureNetLossPerShareSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureNetLossPerShareSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted", "terseLabel": "Net loss per share attributable to common stockholders, diluted", "totalLabel": "Earnings Per Share, Diluted, Total" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDilutedOtherDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted, Other Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Net Loss Per Share" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureNetLossPerShare" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Loss per share" } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateContinuingOperations", "calculation": { "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Percent", "totalLabel": "Total" } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "calculation": { "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "terseLabel": "Statutory rate" } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "calculation": { "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent", "terseLabel": "Change in valuation allowance" } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent", "calculation": { "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent", "terseLabel": "Stock-based compensation" } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "calculation": { "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent", "terseLabel": "State taxes, net of the federal tax benefit" } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch", "calculation": { "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent", "terseLabel": "R&D credit benefit" } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityIncentivePlanAndStockbasedCompensationSummaryOfTotalStockbasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]" } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityIncentivePlanAndStockbasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Unrecognized share-based compensation expense expects to recognize over a weighted-average period" } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "crdr": "debit", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityIncentivePlanAndStockbasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized share-based compensation expense related to unvested share options" } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquitySharesOfCommonStockReservedForFutureIssuanceDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option", "verboseLabel": "ESPP, Authorized for Future Issuance" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "CIK", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r81" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r1" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r79" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r1" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r80" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]" } } }, "auth_ref": [] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": [ "r47" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": [ "r10", "r22", "r32", "r58" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": [ "r7", "r19", "r29", "r55" ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "auth_ref": [ "r53" ] }, "antx_ExistingEmployeesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "ExistingEmployeesMember", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityIncentivePlanAndStockbasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Existing employees.", "label": "Existing Employees [Member]", "terseLabel": "Existing Employees" } } }, "auth_ref": [] }, "antx_FairValueAssetLevel1ToLevel2TransferAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "FairValueAssetLevel1ToLevel2TransferAmount", "crdr": "debit", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Fair value asset level 1 to level 2 transfer amount.", "label": "Fair Value Asset Level 1 To Level 2 Transfer Amount", "terseLabel": "Transfer of level 1 to level 2" } } }, "auth_ref": [] }, "antx_FairValueAssetLevel2ToLevel1TransferAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "FairValueAssetLevel2ToLevel1TransferAmount", "crdr": "debit", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Fair value asset level 2 To level 1 transfer amount.", "label": "Fair Value Asset Level 2 To Level 1 Transfer Amount", "terseLabel": "Transfer of level 2 to level 1" } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsFairValueMeasurementOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsFairValueMeasurementOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]", "terseLabel": "Summary of Financial Assets Fair Value Measurement on Recurring Basis" } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsFairValueMeasurementOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Asset Class [Domain]" } } }, "auth_ref": [] }, "us-gaap_FairValueByAssetClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByAssetClassAxis", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsFairValueMeasurementOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Asset Class [Axis]" } } }, "auth_ref": [] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsFairValueMeasurementOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "auth_ref": [] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsFairValueMeasurementOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Axis]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsFairValueMeasurementOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1" } } }, "auth_ref": [] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsFairValueMeasurementOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2" } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsFairValueMeasurementOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Domain]" } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementInputsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementInputsDisclosureTextBlock", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureFairValueMeasurements1" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementPolicyPolicyTextBlock", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement, Policy [Policy Text Block]", "terseLabel": "Fair Value of Common Stock" } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsFairValueMeasurementOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Domain]" } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsRecurringMember", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsFairValueMeasurementOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring [Member]", "terseLabel": "Fair Value Measurements Recurring" } } }, "auth_ref": [] }, "antx_FairValueOfSharesPerShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "FairValueOfSharesPerShare", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Fair value of shares per share.", "label": "Fair Value Of Shares Per Share", "terseLabel": "Fair value of shares per share" } } }, "auth_ref": [] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialInstrumentAxis", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsFairValueMeasurementOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Financial Instrument [Axis]" } } }, "auth_ref": [] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r14", "r26", "r36", "r62" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r14", "r26", "r36", "r62" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r14", "r26", "r36", "r62" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": [ "r14", "r26", "r36", "r62" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r14", "r26", "r36", "r62" ] }, "antx_FundingArrangementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "FundingArrangementsAbstract", "lang": { "en-us": { "role": { "documentation": "Funding arrangements.", "label": "Funding Arrangements [Abstract]" } } }, "auth_ref": [] }, "antx_FundingArrangementsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "FundingArrangementsTextBlock", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureFundingArrangements" ], "lang": { "en-us": { "role": { "documentation": "Funding arrangements text block.", "label": "Funding Arrangements [Text Block]", "terseLabel": "Funding Arrangements" } } }, "auth_ref": [] }, "antx_FundingOfOptionExtendsEstimatedCompletionOfContractTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "FundingOfOptionExtendsEstimatedCompletionOfContractTerm", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureFundingArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Funding of option extends estimated completion of contract term.", "label": "Funding of Option Extends Estimated Completion of Contract Term", "terseLabel": "Funding of option extends estimated completion of contract term" } } }, "auth_ref": [] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityIncentivePlanAndStockbasedCompensationSummaryOfTotalStockbasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "General and Administrative Expense [Member]", "terseLabel": "General and Administrative Expense" } } }, "auth_ref": [] }, "us-gaap_GovernmentAssistanceLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GovernmentAssistanceLineItems", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureFundingArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Government Assistance [Line Items]" } } }, "auth_ref": [] }, "us-gaap_GovernmentAssistanceTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GovernmentAssistanceTable", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureFundingArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Government Assistance [Table]" } } }, "auth_ref": [] }, "us-gaap_GovernmentAssistanceTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GovernmentAssistanceTypeAxis", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureFundingArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Government Assistance, Type [Axis]" } } }, "auth_ref": [] }, "us-gaap_GovernmentAssistanceTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GovernmentAssistanceTypeDomain", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureFundingArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Government Assistance, Type [Domain]" } } }, "auth_ref": [] }, "antx_GovernmentAward": { "xbrltype": "monetaryItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "GovernmentAward", "crdr": "credit", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureFundingArrangementsAdditionalInformationDetails", "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Maximum amount eligible to receive under cost-reimbursement contract award", "documentation": "Government award", "label": "Government Award", "terseLabel": "Government award" } } }, "auth_ref": [] }, "antx_GovernmentContractFundingIncreasedAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "GovernmentContractFundingIncreasedAmount", "crdr": "credit", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureFundingArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Government contract funding increased amount.", "label": "Government Contract Funding Increased Amount", "terseLabel": "Government contract fund increased amount" } } }, "auth_ref": [] }, "antx_GovernmentContractIncomeRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "GovernmentContractIncomeRecognized", "crdr": "credit", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureFundingArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Government contract income recognized.", "label": "Government Contract Income Recognized", "terseLabel": "Government contract income recognized" } } }, "auth_ref": [] }, "us-gaap_GovernmentContractReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GovernmentContractReceivable", "crdr": "debit", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureFundingArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Government Contract Receivable", "terseLabel": "Government contract receivable" } } }, "auth_ref": [] }, "antx_GovernmentContractReceivedDuringYear": { "xbrltype": "monetaryItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "GovernmentContractReceivedDuringYear", "crdr": "credit", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureFundingArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Government contract received during year.", "label": "Government Contract Received During Year", "terseLabel": "Government contract received during year" } } }, "auth_ref": [] }, "antx_GovernmentContractRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "GovernmentContractRevenueRecognized", "crdr": "credit", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureFundingArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Government contract revenue recognized.", "label": "Government Contract Revenue Recognized", "terseLabel": "Government contract revenue recognized" } } }, "auth_ref": [] }, "us-gaap_GovernmentContractorsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GovernmentContractorsPolicyPolicyTextBlock", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Government Contractors, Policy [Policy Text Block]", "terseLabel": "Government Contract" } } }, "auth_ref": [] }, "antx_GrantAgreementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "GrantAgreementsPolicyPolicyTextBlock", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "Grant Agreements.", "label": "Grant Agreements, Policy [Policy Text Block]", "terseLabel": "Grant Agreements" } } }, "auth_ref": [] }, "antx_GrantAwardAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "GrantAwardAmount", "crdr": "credit", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureFundingArrangementsAdditionalInformationDetails", "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Grant award amount.", "label": "Grant Award Amount", "terseLabel": "Grant award amount" } } }, "auth_ref": [] }, "antx_GrantFundingInAdvanceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "GrantFundingInAdvanceAmount", "crdr": "debit", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureFundingArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Grant funding in advance amount.", "label": "Grant Funding In Advance Amount", "terseLabel": "Grant funding in advance amount" } } }, "auth_ref": [] }, "antx_GrantIncomeRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "GrantIncomeRecognized", "crdr": "credit", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureFundingArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Grant income recognized.", "label": "Grant Income Recognized", "terseLabel": "Grant income recognized" } } }, "auth_ref": [] }, "us-gaap_GrantsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GrantsReceivable", "crdr": "debit", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureFundingArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Grants Receivable", "terseLabel": "Grant receivable" } } }, "auth_ref": [] }, "antx_GrossProceedsFromInitialPublicOffering": { "xbrltype": "monetaryItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "GrossProceedsFromInitialPublicOffering", "crdr": "debit", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Gross Proceeds from Initial Public Offering", "label": "Gross Proceeds from Initial Public Offering", "terseLabel": "Aggregate offering price for shares sold", "verboseLabel": "Total gross proceeds" } } }, "auth_ref": [] }, "us-gaap_IPOMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IPOMember", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails", "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "IPO [Member]", "terseLabel": "Initial Public Offering" } } }, "auth_ref": [] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r4", "r5", "r18" ] }, "us-gaap_ImpairmentOfInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOfInvestments", "crdr": "debit", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Other than Temporary Impairment Losses, Investments", "terseLabel": "Impairment losses related to investments" } } }, "auth_ref": [] }, "antx_IncentiveStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "IncentiveStockOptionMember", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityIncentivePlanAndStockbasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Incentive stock option.", "label": "Incentive Stock Option [Member]", "terseLabel": "Incentive Stock Option" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityIncentivePlanAndStockbasedCompensationSummaryOfTotalStockbasedCompensationDetails", "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Income Statement Location [Axis]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityIncentivePlanAndStockbasedCompensationSummaryOfTotalStockbasedCompensationDetails", "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Income Statement Location [Domain]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxAuthorityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxAuthorityAxis", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Income Tax Authority [Axis]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxAuthorityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxAuthorityDomain", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Income Tax Authority [Domain]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxAuthorityNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxAuthorityNameAxis", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Income Tax Authority, Name [Axis]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxAuthorityNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxAuthorityNameDomain", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Income Tax Authority, Name [Domain]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureIncomeTaxes" ], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax Disclosure [Text Block]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureIncomeTaxesProvisionForIncomeTaxesDiffersFromTaxExpenseDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails", "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureIncomeTaxesProvisionForIncomeTaxesDiffersFromTaxExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax liability or expense", "totalLabel": "Provision for income taxes", "label": "Income Tax Expense (Benefit)" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "crdr": "debit", "calculation": { "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureIncomeTaxesProvisionForIncomeTaxesDiffersFromTaxExpenseDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureIncomeTaxesProvisionForIncomeTaxesDiffersFromTaxExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in valuation allowance", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "crdr": "debit", "calculation": { "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureIncomeTaxesProvisionForIncomeTaxesDiffersFromTaxExpenseDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureIncomeTaxesProvisionForIncomeTaxesDiffersFromTaxExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Federal tax benefit at statutory rate", "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxReconciliationOtherAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationOtherAdjustments", "crdr": "debit", "calculation": { "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureIncomeTaxesProvisionForIncomeTaxesDiffersFromTaxExpenseDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureIncomeTaxesProvisionForIncomeTaxesDiffersFromTaxExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes", "crdr": "debit", "calculation": { "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureIncomeTaxesProvisionForIncomeTaxesDiffersFromTaxExpenseDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureIncomeTaxesProvisionForIncomeTaxesDiffersFromTaxExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "State tax benefit at statutory rate, net of federal tax benefit", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationTaxCreditsResearch", "crdr": "credit", "calculation": { "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureIncomeTaxesProvisionForIncomeTaxesDiffersFromTaxExpenseDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureIncomeTaxesProvisionForIncomeTaxesDiffersFromTaxExpenseDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Research and development tax credits", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount" } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": [ "r17", "r26", "r36", "r53", "r62", "r66", "r74" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": [ "r72" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": [ "r6", "r78" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": [ "r6", "r78" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": [ "r6", "r78" ] }, "us-gaap_InterestReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestReceivableCurrent", "crdr": "debit", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Interest Receivable, Current", "terseLabel": "Accrued interest receivable" } } }, "auth_ref": [] }, "us-gaap_InvestmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentPolicyTextBlock", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Investment, Policy [Policy Text Block]", "terseLabel": "Investments" } } }, "auth_ref": [] }, "us-gaap_InvestmentTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentTypeAxis", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsFairValueMeasurementOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Investment Type [Axis]" } } }, "auth_ref": [] }, "us-gaap_InvestmentTypeCategorizationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentTypeCategorizationMember", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsFairValueMeasurementOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Investments [Domain]" } } }, "auth_ref": [] }, "us-gaap_Investments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Investments", "crdr": "debit", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Investments", "terseLabel": "Investments", "totalLabel": "Investments, Total" } } }, "auth_ref": [] }, "antx_JobsActAccountingElectionPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "JobsActAccountingElectionPolicyPolicyTextBlock", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "Jobs act accounting election policy.", "label": "Jobs Act Accounting Election Policy [Policy Text Block]", "terseLabel": "JOBS Act Accounting Election" } } }, "auth_ref": [] }, "antx_JosephZakrzewskiMember": { "xbrltype": "domainItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "JosephZakrzewskiMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "documentation": "Joseph Zakrzewski.", "label": "Joseph Zakrzewski [Member]", "terseLabel": "Joseph Zakrzewski" } } }, "auth_ref": [] }, "us-gaap_LeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCost", "crdr": "debit", "calculation": { "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfTotalLeaseExpenseDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfTotalLeaseExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Lease, Cost", "totalLabel": "Total lease expense" } } }, "auth_ref": [] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCostTableTextBlock", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureLeasesTables" ], "lang": { "en-us": { "role": { "label": "Lease, Cost [Table Text Block]", "terseLabel": "Summary of Total Lease Expense" } } }, "auth_ref": [] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LesseeLeaseDescriptionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeaseDescriptionLineItems", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Lease, Description [Line Items]" } } }, "auth_ref": [] }, "us-gaap_LesseeLeaseDescriptionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeaseDescriptionTable", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Lease, Description [Table]" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureLeasesTables" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "terseLabel": "Summary of Maturities of Lease Liabilities" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseOptionToExtend": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseOptionToExtend", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Option to Extend", "terseLabel": "Option to extend" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseRenewalTerm", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Renewal Term", "terseLabel": "Operating lease renewal term" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureLeases" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Leases" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "antx_LongTermInvestmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "LongTermInvestmentsMember", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsFairValueMeasurementOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "documentation": "Long term investments.", "label": "Long Term Investments [Member]", "terseLabel": "Long-term investments" } } }, "auth_ref": [] }, "us-gaap_LongtermPurchaseCommitmentPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermPurchaseCommitmentPeriod", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Purchase Commitment, Period", "terseLabel": "Long term purchase commitment period" } } }, "auth_ref": [] }, "us-gaap_LossContingenciesByNatureOfContingencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingenciesByNatureOfContingencyAxis", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Loss Contingency Nature [Axis]" } } }, "auth_ref": [] }, "us-gaap_LossContingencyNatureDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingencyNatureDomain", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Loss Contingency, Nature [Domain]" } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails", "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityIncentivePlanAndStockbasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "auth_ref": [] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "auth_ref": [ "r45" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": [ "r45" ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityIncentivePlanAndStockbasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "auth_ref": [] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": [ "r65" ] }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MoneyMarketFundsMember", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsFairValueMeasurementOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Money Market Funds [Member]", "terseLabel": "Money Market Funds" } } }, "auth_ref": [] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": [ "r73" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": [ "r46" ] }, "antx_NationalInstituteOfAllergyAndInfectiousDiseasesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "NationalInstituteOfAllergyAndInfectiousDiseasesMember", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureFundingArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "National Institute of Allergy and Infectious Diseases", "label": "National Institute of Allergy and Infectious Diseases [Member]", "terseLabel": "NIAID Contract" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities", "terseLabel": "Cash flows used in operating activities", "totalLabel": "Net cash used in operating activities", "verboseLabel": "Cash flows used in operating activities", "negatedLabel": "Cash flows used in operating activities" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureNetLossPerShareSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetails": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureNetLossPerShareSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetails", "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "totalLabel": "Net loss", "negatedLabel": "Net loss", "verboseLabel": "Net loss" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "calculation": { "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureNetLossPerShareSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureNetLossPerShareSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Basic", "terseLabel": "Net loss attributable to common stockholders", "totalLabel": "Net loss attributable to common stockholders" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureNetLossPerShareSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]", "terseLabel": "Numerator:" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Adopted Accounting Pronouncements" } } }, "auth_ref": [] }, "antx_NewlyHiredEmployeesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "NewlyHiredEmployeesMember", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityIncentivePlanAndStockbasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Newly Hired Employees.", "label": "Newly Hired Employees [Member]", "terseLabel": "Newly Hired Employees" } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": [ "r45" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": [ "r14", "r26", "r36", "r53", "r62" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r43" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r42" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": [ "r53" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r73" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r73" ] }, "antx_NonStatutoryStockOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "NonStatutoryStockOptionsMember", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityIncentivePlanAndStockbasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Non statutory stock options.", "label": "Non Statutory Stock Options [Member]", "terseLabel": "Non-Statutory Stock Options" } } }, "auth_ref": [] }, "antx_NumberOfAvailableOptionsUnderGovernmentContract": { "xbrltype": "integerItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "NumberOfAvailableOptionsUnderGovernmentContract", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureFundingArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of available options under government contract.", "label": "Number of Available Options under Government Contract", "terseLabel": "Number of available options under government contract" } } }, "auth_ref": [] }, "antx_NumberOfDaysConvenienceUponWrittenNoticeThereafter": { "xbrltype": "durationItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "NumberOfDaysConvenienceUponWrittenNoticeThereafter", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of days convenience upon written notice thereafter.", "label": "Number Of Days Convenience Upon Written Notice Thereafter", "terseLabel": "Number of days convenience upon written notice thereafter" } } }, "auth_ref": [] }, "antx_NumberOfDaysConvenienceUponWrittenNoticeUntilFirstRegulatoryApproval": { "xbrltype": "durationItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "NumberOfDaysConvenienceUponWrittenNoticeUntilFirstRegulatoryApproval", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of days convenience upon written notice until first regulatory approval.", "label": "Number Of Days Convenience Upon Written Notice Until First Regulatory Approval", "terseLabel": "Number of days convenience upon written notice until first regulatory approval." } } }, "auth_ref": [] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfOperatingSegments", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Number of Operating Segments", "terseLabel": "Number of operating segments" } } }, "auth_ref": [] }, "antx_NumberOfOptionExercisedForGovernmentContract": { "xbrltype": "integerItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "NumberOfOptionExercisedForGovernmentContract", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureFundingArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of option exercised for government contract.", "label": "Number of Option Exercised for Government Contract", "terseLabel": "Number of option exercised for government contract" } } }, "auth_ref": [] }, "antx_NumberOfOptionPeriodForFundingFromGovernmentContract": { "xbrltype": "durationItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "NumberOfOptionPeriodForFundingFromGovernmentContract", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureFundingArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of option period for funding from government contract.", "label": "Number of Option Period for Funding From Government Contract", "terseLabel": "Number of option period for funding from government contract" } } }, "auth_ref": [] }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfReportableSegments", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Number of Reportable Segments", "terseLabel": "Number of reportable Segments" } } }, "auth_ref": [] }, "antx_NumberOfYearsSalesRoyaltyRequiredToBePaid": { "xbrltype": "durationItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "NumberOfYearsSalesRoyaltyRequiredToBePaid", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of years sales royalty required to be paid.", "label": "Number of Years Sales Royalty Required to Be Paid", "terseLabel": "Number of years, sales royalty required to be paid" } } }, "auth_ref": [] }, "antx_OfferingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "OfferingCosts", "crdr": "debit", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Offering costs.", "label": "Offering Costs" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseCost", "crdr": "debit", "calculation": { "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfTotalLeaseExpenseDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfTotalLeaseExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Cost", "terseLabel": "Operating lease expense" } } }, "auth_ref": [] }, "antx_OperatingLeaseExpirationDate": { "xbrltype": "gYearMonthItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "OperatingLeaseExpirationDate", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Operating lease, expiration date", "label": "Operating Lease, expiration date", "terseLabel": "Operating lease extended expiration date" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Leases, Total lease liabilities", "label": "Operating Lease, Liability", "totalLabel": "Operating Lease, Liability, Total", "verboseLabel": "Operating lease liabilities" } } }, "auth_ref": [] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Payments", "terseLabel": "Operating cash flows from operating leases" } } }, "auth_ref": [] }, "antx_OperatingLeaseRenewalPeriod": { "xbrltype": "gYearMonthItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "OperatingLeaseRenewalPeriod", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Operating lease, renewal period.", "label": "Operating Lease, Renewal period", "terseLabel": "Operating lease renewal option period" } } }, "auth_ref": [] }, "antx_OperatingLeaseRightOfUseAssetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "OperatingLeaseRightOfUseAssetCurrent", "crdr": "debit", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Operating lease right-of-use assets", "documentation": "Operating lease right of use asset current", "terseLabel": "Right-of-use asset, net", "verboseLabel": "Right-of-use asset, net" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average remaining discounted rate", "label": "Operating Lease, Weighted Average Discount Rate, Percent" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted-average remaining lease term" } } }, "auth_ref": [] }, "us-gaap_OperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLossCarryforwards", "crdr": "debit", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net operating loss carryforwards", "label": "Operating Loss Carryforwards" } } }, "auth_ref": [] }, "antx_OperatingLossCarryforwardsExpirationYear": { "xbrltype": "gYearItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "OperatingLossCarryforwardsExpirationYear", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Operating loss carryforwards, expiration year", "terseLabel": "Operating loss carryforwards, expiration year", "label": "Operating Loss Carryforwards, Expiration Year" } } }, "auth_ref": [] }, "us-gaap_OperatingLossCarryforwardsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLossCarryforwardsLineItems", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Operating Loss Carryforwards [Line Items]" } } }, "auth_ref": [] }, "us-gaap_OperatingLossCarryforwardsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLossCarryforwardsTable", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Operating Loss Carryforwards [Table]" } } }, "auth_ref": [] }, "antx_OptionIssuedAndOutstandingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "OptionIssuedAndOutstandingMember", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationDetails" ], "lang": { "en-us": { "role": { "documentation": "Option issued and outstanding.", "label": "Option Issued And Outstanding [Member]", "terseLabel": "Option Issued and Outstanding" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusiness" ], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]", "terseLabel": "Organization and Description of Business" } } }, "auth_ref": [] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Other Accrued Liabilities, Current", "terseLabel": "Other" } } }, "auth_ref": [] }, "antx_OtherDirectorsOrOfficersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "OtherDirectorsOrOfficersMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "documentation": "Other directors or officers.", "label": "Other Directors or Officers [Member]", "terseLabel": "Other Directors or Officers" } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureFundingArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Other Liabilities, Current", "terseLabel": "Other liabilities current", "verboseLabel": "Other current liabilities" } } }, "auth_ref": [] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r45" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r12", "r24", "r34", "r60" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": [ "r15", "r27", "r37", "r63" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r15", "r27", "r37", "r63" ] }, "us-gaap_OverAllotmentOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OverAllotmentOptionMember", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Over-Allotment Option [Member]", "terseLabel": "Underwriters" } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r41" ] }, "antx_PaymentOfNonRefundableUpfrontPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "PaymentOfNonRefundableUpfrontPayment", "crdr": "debit", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Payment of non-refundable upfront payment.", "label": "Payment Of Non Refundable Upfront Payment", "terseLabel": "Payment of non-refundable upfront payment" } } }, "auth_ref": [] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": [ "r44" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r44" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r43" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": [ "r53" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": [ "r46" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r42" ] }, "antx_PercentageOfAnnualIncreaseInSharesReservedForFutureIssuanceOnCommonStockOutstanding": { "xbrltype": "percentItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "PercentageOfAnnualIncreaseInSharesReservedForFutureIssuanceOnCommonStockOutstanding", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityIncentivePlanAndStockbasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of annual increase in shares reserved for future issuance on common stock outstanding.", "label": "Percentage of annual increase in shares reserved for future issuance on common stock outstanding." } } }, "auth_ref": [] }, "antx_PercentageOfMaximumCommissionsToBePaidToAgentOfGrossProceedsOfSale": { "xbrltype": "percentItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "PercentageOfMaximumCommissionsToBePaidToAgentOfGrossProceedsOfSale", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of maximum commissions to be paid to agent of gross proceeds of sale.", "label": "Percentage Of Maximum Commissions To Be Paid To Agent Of Gross Proceeds Of Sale", "terseLabel": "Percentage of maximum commissions to be paid to agent of gross proceeds of sale" } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameAxis", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityIncentivePlanAndStockbasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]" } } }, "auth_ref": [] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameDomain", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityIncentivePlanAndStockbasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Plan Name [Domain]" } } }, "auth_ref": [] }, "us-gaap_PreferredStockDividendsAndOtherAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockDividendsAndOtherAdjustments", "crdr": "debit", "calculation": { "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureNetLossPerShareSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetails": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureNetLossPerShareSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Preferred Stock Dividends and Other Adjustments", "terseLabel": "Accretion to redemption value and cumulative dividends on preferred stock", "totalLabel": "Preferred Stock Dividends and Other Adjustments, Total", "negatedLabel": "Accretion to redemption value and cumulative dividends on preferred stock" } } }, "auth_ref": [] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value" } } }, "auth_ref": [] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized" } } }, "auth_ref": [] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesIssued", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued" } } }, "auth_ref": [] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Outstanding", "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance", "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance", "terseLabel": "Preferred stock, shares outstanding" } } }, "auth_ref": [] }, "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpensesAndOtherCurrentAssetsMember", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Prepaid Expenses and Other Current Assets [Member]", "terseLabel": "Prepaid Expenses and Other Current Assets" } } }, "auth_ref": [] }, "antx_ProceedsFromGovernmentContract": { "xbrltype": "monetaryItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "ProceedsFromGovernmentContract", "crdr": "debit", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureFundingArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Proceeds from government contract.", "label": "Proceeds from Government Contract", "terseLabel": "Proceeds from government contract" } } }, "auth_ref": [] }, "antx_ProceedsFromInvestment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "ProceedsFromInvestment", "crdr": "debit", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from Investment", "documentation": "Proceeds from investment", "label": "Proceeds From Investment" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceInitialPublicOffering", "crdr": "debit", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance Initial Public Offering", "terseLabel": "Proceeds from issuance of common stock from the initial public offering, net of underwriting discounts, commissions and offering expenses", "verboseLabel": "Net proceeds from offering" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityAdditionalInformationDetails", "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails", "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Net proceeds from issuance of common stock", "terseLabel": "Proceeds from issuance of common stock under the ESPP", "label": "Proceeds from Issuance of Common Stock" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt", "crdr": "debit", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Proceeds from Sale of Debt Securities, Available-for-Sale", "terseLabel": "Available-for-sale, sale of investments" } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r41" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": [ "r41" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails", "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityIncentivePlanAndStockbasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails", "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityIncentivePlanAndStockbasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [] }, "antx_RecentAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "RecentAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "Recent accounting pronouncements not yet adopted policy.", "label": "Recent Accounting Pronouncements Not Yet Adopted Policy [Policy Text Block]", "terseLabel": "Recent Accounting Pronouncements Not Yet Adopted" } } }, "auth_ref": [] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": [ "r7", "r19", "r29", "r55" ] }, "antx_RedeemableConvertiblePreferredStockPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "RedeemableConvertiblePreferredStockPolicyTextBlock", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "Redeemable convertible preferred stock.", "label": "Redeemable Convertible Preferred Stock [Policy Text Block]", "verboseLabel": "Redeemable Convertible Preferred Stock" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionLineItems", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Line Items]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactions" ], "lang": { "en-us": { "role": { "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related Party Transactions" } } }, "auth_ref": [] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]" } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Research and Development Expense", "totalLabel": "Research and Development Expense, Total", "terseLabel": "Research and development" } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityIncentivePlanAndStockbasedCompensationSummaryOfTotalStockbasedCompensationDetails", "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Research and Development Expense [Member]", "terseLabel": "Research and Development Expense" } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and Development Expenses" } } }, "auth_ref": [] }, "antx_ResearchAndDevelopmentExpenseRelatedParty": { "xbrltype": "monetaryItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "ResearchAndDevelopmentExpenseRelatedParty", "crdr": "debit", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development expense related party", "label": "Research and development expense related party", "documentation": "Research and development expense related party." } } }, "auth_ref": [] }, "antx_ResearchAndDevelopmentRelatedExpensesRelatedParty": { "xbrltype": "monetaryItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "ResearchAndDevelopmentRelatedExpensesRelatedParty", "crdr": "debit", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Research and development related expenses related party.", "label": "Research and Development Related Expenses Related Party", "terseLabel": "Research and development related expense related party" } } }, "auth_ref": [] }, "us-gaap_ResearchMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchMember", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research Tax Credit Carryforward [Member]" } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": [ "r8", "r20", "r30", "r56" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": [ "r9", "r21", "r31", "r57" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": [ "r16", "r28", "r38", "r64" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Retained Earnings (Accumulated Deficit)", "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance", "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance", "terseLabel": "Accumulated deficit", "totalLabel": "Retained Earnings (Accumulated Deficit), Total", "verboseLabel": "Accumulated deficit", "negatedLabel": "Accumulated deficit" } } }, "auth_ref": [] }, "antx_RisksAndUncertaintiesPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "RisksAndUncertaintiesPolicyPolicyTextBlock", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "Risks and Uncertainties Policy Policy Text Block", "label": "Risks and Uncertainties Policy Policy Text Block", "terseLabel": "Risks and Uncertainties" } } }, "auth_ref": [] }, "antx_RoyaltyPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "RoyaltyPercentage", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Royalty percentage.", "label": "Royalty Percentage", "terseLabel": "Royalty percentage" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r73" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r73" ] }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockConsiderationReceivedOnTransaction", "crdr": "debit", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityAdditionalInformationDetails", "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Sale of Stock, Consideration Received on Transaction", "terseLabel": "Aggregate gross sales" } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityAdditionalInformationDetails", "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails", "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Domain]" } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityAdditionalInformationDetails", "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Sale of Stock, Number of Shares Issued in Transaction", "terseLabel": "Common stock issued and sold", "verboseLabel": "Common stock, shares sold" } } }, "auth_ref": [] }, "antx_SalesAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "SalesAgreementMember", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityAdditionalInformationDetails", "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Sales Agreement.", "label": "Sales Agreement [Member]", "terseLabel": "Sales Agreement" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Balance Sheet Components" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureNetLossPerShareTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of potentially dilutive securities that were not included in the diluted per share" } } }, "auth_ref": [] }, "antx_ScheduleOfCommonStockSharesReservedForFutureIssuance": { "xbrltype": "textBlockItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "ScheduleOfCommonStockSharesReservedForFutureIssuance", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityTables" ], "lang": { "en-us": { "role": { "documentation": "Schedule of common stock shares reserved for future issuance.", "label": "Schedule Of Common Stock Shares Reserved For Future Issuance", "terseLabel": "Schedule of Shares of Common Stock Reserved for Future Issuance" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureIncomeTaxesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Components of Deferred Tax Assets", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureNetLossPerShareTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of computation of basic and diluted net loss per share" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureNetLossPerShareSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureIncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "verboseLabel": "Schedule of Effective Income Tax Rate Reconciliation", "terseLabel": "Provision for Income Taxes Differs from Tax Expense and Effective Income Tax Rate Reconciliations" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityIncentivePlanAndStockbasedCompensationSummaryOfTotalStockbasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityIncentivePlanAndStockbasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Summary of Total Stock-Based Compensation" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityIncentivePlanAndStockbasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityIncentivePlanAndStockbasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Summary of Stock Plan Activity" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityIncentivePlanAndStockbasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Weighted Average Assumptions Used to Value Options Granted", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockByClassTable", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityAdditionalInformationDetails", "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquitySharesOfCommonStockReservedForFutureIssuanceDetails", "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Stock by Class [Table]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureIncomeTaxesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits", "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r3" ] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Segment Reporting, Policy [Policy Text Block]", "terseLabel": "Segments" } } }, "auth_ref": [] }, "antx_SeriesARedeemableConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "SeriesARedeemableConvertiblePreferredStockMember", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails", "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquitySharesOfCommonStockReservedForFutureIssuanceDetails" ], "lang": { "en-us": { "role": { "documentation": "Series A redeemable convertible preferred stock.", "label": "Series A Redeemable Convertible Preferred Stock [Member]", "terseLabel": "Series A Redeemable Convertible Preferred Stock", "verboseLabel": "Series A" } } }, "auth_ref": [] }, "antx_SeriesBRedeemableConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "SeriesBRedeemableConvertiblePreferredStockMember", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquitySharesOfCommonStockReservedForFutureIssuanceDetails" ], "lang": { "en-us": { "role": { "documentation": "Series D redeemable convertible preferred stock.", "label": "Series B Redeemable Convertible Preferred Stock [Member]", "terseLabel": "Series B Redeemable Convertible Preferred Stock", "verboseLabel": "Series B" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityIncentivePlanAndStockbasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period", "terseLabel": "Rights to repurchase shares, service period" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityIncentivePlanAndStockbasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "terseLabel": "Vesting period" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityIncentivePlanAndStockbasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights", "terseLabel": "Rights to repurchase shares, description" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Aggregate granted shares", "verboseLabel": "Number of shares issued" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityIncentivePlanAndStockbasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance", "periodStartLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Beginning Balance", "terseLabel": "Number of shares issued" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments", "crdr": "debit", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Payments", "terseLabel": "Assumed dividend yield" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityIncentivePlanAndStockbasedCompensationAdditionalInformationDetails", "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityIncentivePlanAndStockbasedCompensationSummaryOfWeightedAverageAssumptionsUsedToValueOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected dividend yield", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityIncentivePlanAndStockbasedCompensationSummaryOfWeightedAverageAssumptionsUsedToValueOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected volatility", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityIncentivePlanAndStockbasedCompensationSummaryOfWeightedAverageAssumptionsUsedToValueOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risk-free interest rate", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate" } } }, "auth_ref": [] }, "antx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfShares", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityIncentivePlanAndStockbasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase in number of annual shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Increase in Number of Shares", "documentation": "Share-based compensation arrangement by share-based payment award, increase in number of shares." } } }, "auth_ref": [] }, "antx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreasePercentageOfCommonStockOutstanding": { "xbrltype": "percentItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreasePercentageOfCommonStockOutstanding", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityIncentivePlanAndStockbasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of common stock outstanding", "label": "Share Based Compensation Arrangement By Share Based Payment Award Increase Percentage Of Common Stock Outstanding", "documentation": "Share based compensation arrangement by share based payment award increase percentage of common stock outstanding." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityIncentivePlanAndStockbasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityIncentivePlanAndStockbasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum percentage in payroll deductions to purchase shares of common stock", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityIncentivePlanAndStockbasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "terseLabel": "Maximum number of shares of common stock that may be issued" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityIncentivePlanAndStockbasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "periodEndLabel": "Options available for grant, Ending balance", "periodStartLabel": "Options available for grant, Beginning balance", "terseLabel": "Shares of common stock remained available for future issuance" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityIncentivePlanAndStockbasedCompensationSummaryOfStockPlanActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "terseLabel": "Total Options Outstanding, Exercisable" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityIncentivePlanAndStockbasedCompensationSummaryOfStockPlanActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price per Share, Exercisable" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityIncentivePlanAndStockbasedCompensationSummaryOfStockPlanActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "terseLabel": "Total Options Outstanding, Forfeited", "negatedLabel": "Total Options Outstanding, Forfeited" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityIncentivePlanAndStockbasedCompensationSummaryOfStockPlanActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Total Options outstanding, Granted" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityIncentivePlanAndStockbasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average grant-date fair value, options granted" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityIncentivePlanAndStockbasedCompensationSummaryOfStockPlanActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Outstanding" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityIncentivePlanAndStockbasedCompensationSummaryOfStockPlanActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Total Options outstanding, Ending balance", "periodStartLabel": "Total Options outstanding, Beginning balance", "terseLabel": "Options outstanding" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityIncentivePlanAndStockbasedCompensationSummaryOfStockPlanActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted average exercise price, Ending balance", "periodStartLabel": "Weighted average exercise price, Beginning balance", "terseLabel": "Weighted average exercise price per share, Outstanding" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityIncentivePlanAndStockbasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares of common stock available for purchase", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Purchased for Award" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityIncentivePlanAndStockbasedCompensationAdditionalInformationDetails", "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquitySharesOfCommonStockReservedForFutureIssuanceDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityIncentivePlanAndStockbasedCompensationSummaryOfStockPlanActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price, Exercised" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityIncentivePlanAndStockbasedCompensationSummaryOfStockPlanActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price, Forfeited" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityIncentivePlanAndStockbasedCompensationSummaryOfStockPlanActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price, Granted" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationAwardTrancheOneMember", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityIncentivePlanAndStockbasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Tranche One [Member]", "terseLabel": "After Completion of 12 months of Service" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationAwardTrancheThreeMember", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityIncentivePlanAndStockbasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Tranche Three [Member]", "terseLabel": "Over 48 months of Service" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationAwardTrancheTwoMember", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityIncentivePlanAndStockbasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Tranche Two [Member]", "terseLabel": "Over 36 months of Service" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Policy Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "auth_ref": [] }, "antx_ShareBasedPaymentArrangementUnvestedSharesOutstandingIssuedUponEarlyExerciseOfStockOptions": { "xbrltype": "sharesItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "ShareBasedPaymentArrangementUnvestedSharesOutstandingIssuedUponEarlyExerciseOfStockOptions", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityIncentivePlanAndStockbasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement, unvested shares outstanding issued upon early exercise of stock options.", "label": "Share-based Payment Arrangement, Unvested Shares Outstanding Issued Upon Early Exercise of Stock Options", "terseLabel": "Unvested common shares outstanding were issued upon early exercise of stock options" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityIncentivePlanAndStockbasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage", "terseLabel": "Vesting percentage" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityIncentivePlanAndStockbasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "terseLabel": "Award contractual life (in years)" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityIncentivePlanAndStockbasedCompensationSummaryOfWeightedAverageAssumptionsUsedToValueOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected term", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityIncentivePlanAndStockbasedCompensationSummaryOfStockPlanActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Exercisable" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityIncentivePlanAndStockbasedCompensationSummaryOfStockPlanActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Remaining Contractual Life, Exercisable" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityIncentivePlanAndStockbasedCompensationSummaryOfStockPlanActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Remaining Contractual Life, Outstanding" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityIncentivePlanAndStockbasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employees purchase price of common stock as percentage of lower of fair market value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent" } } }, "auth_ref": [] }, "antx_SharesGrantedPerSharePricePaid": { "xbrltype": "perShareItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "SharesGrantedPerSharePricePaid", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Shares granted per share price paid.", "label": "Shares Granted Per Share Price Paid", "terseLabel": "Shares granted per share price paid" } } }, "auth_ref": [] }, "us-gaap_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesIssuedPricePerShare", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityAdditionalInformationDetails", "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Shares Issued, Price Per Share", "terseLabel": "Original issue price", "verboseLabel": "Stock issued, price per share" } } }, "auth_ref": [] }, "us-gaap_ShortTermInvestmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermInvestmentsMember", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsFairValueMeasurementOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Short-Term Investments [Member]", "terseLabel": "Short-term investments" } } }, "auth_ref": [] }, "us-gaap_ShortTermLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermLeaseCost", "crdr": "debit", "calculation": { "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfTotalLeaseExpenseDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfTotalLeaseExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Short-Term Lease, Cost", "terseLabel": "Short-term lease expense" } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies1" ], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "auth_ref": [] }, "us-gaap_StateAndLocalJurisdictionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StateAndLocalJurisdictionMember", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "State", "label": "State and Local Jurisdiction [Member]" } } }, "auth_ref": [] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails", "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquitySharesOfCommonStockReservedForFutureIssuanceDetails" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "auth_ref": [] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]" } } }, "auth_ref": [] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": [ "r11", "r23", "r33", "r59" ] }, "antx_StockAppreciationRightsRestrictedStockRestrictedStockUnitOrPerformanceAwardsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "StockAppreciationRightsRestrictedStockRestrictedStockUnitOrPerformanceAwardsMember", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityIncentivePlanAndStockbasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Stock appreciation rights, restricted stock, restricted stock unit or performance awards.", "label": "Stock Appreciation Rights, Restricted Stock, Restricted Stock Unit or Performance Awards [Member]", "terseLabel": "Stock Appreciation Rights, Restricted Stock Award, Restricted Stock Unit or Performance Awards" } } }, "auth_ref": [] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, New Issues", "verboseLabel": "Issuance of common stock, net of commissions and offering costs, shares", "terseLabel": "Aggregate number of shares issued" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityIncentivePlanAndStockbasedCompensationSummaryOfStockPlanActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "terseLabel": "Options exercised", "negatedLabel": "Total Options Outstanding, Exercised", "verboseLabel": "Issuance of common stock upon exercise of stock options shares" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Stock issued during period, value, new issues", "verboseLabel": "Issuance of common stock, net of commissions and offering costs" } } }, "auth_ref": [] }, "antx_StockOptionsAuthorizedForFutureIssuanceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "StockOptionsAuthorizedForFutureIssuanceMember", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquitySharesOfCommonStockReservedForFutureIssuanceDetails" ], "lang": { "en-us": { "role": { "documentation": "Stock options authorized for future issuance.", "label": "Stock Options Authorized For Future Issuance [Member]", "terseLabel": "Stock Options Authorized For Future Issuance" } } }, "auth_ref": [] }, "antx_StockOptionsIssuedAndOutstandingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "StockOptionsIssuedAndOutstandingMember", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquitySharesOfCommonStockReservedForFutureIssuanceDetails" ], "lang": { "en-us": { "role": { "documentation": "Stock options issued and outstanding.", "label": "Stock Options Issued And Outstanding [Member]", "terseLabel": "Stock Options Issued And Outstanding" } } }, "auth_ref": [] }, "antx_StockSplitPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "StockSplitPolicyPolicyTextBlock", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "Stock split policy", "label": "Stock Split Policy Policy Text Block", "verboseLabel": "Stock Split" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquity2" ], "lang": { "en-us": { "role": { "label": "Equity [Text Block]", "terseLabel": "Equity", "verboseLabel": "Redeemable Convertible Preferred Stock" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteStockSplit": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteStockSplit", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note, Stock Split", "terseLabel": "Stockholders' equity forward stock split" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": { "xbrltype": "pureItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteStockSplitConversionRatio1", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio", "terseLabel": "Stockholders' equity forward stock split, conversion ratio" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureSubsequentEvents" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Events", "label": "Subsequent Events [Text Block]" } } }, "auth_ref": [] }, "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]" } } }, "auth_ref": [] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityAdditionalInformationDetails", "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails", "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]" } } }, "auth_ref": [] }, "us-gaap_SubsidiarySaleOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsidiarySaleOfStockLineItems", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Subsidiary, Sale of Stock [Line Items]" } } }, "auth_ref": [] }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureBalanceSheetComponents1" ], "lang": { "en-us": { "role": { "label": "Supplemental Balance Sheet Disclosures [Text Block]", "terseLabel": "Balance Sheet Components" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": [ "r52" ] }, "us-gaap_TaxCreditCarryforwardAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxCreditCarryforwardAmount", "crdr": "debit", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax credit carryforwards", "label": "Tax Credit Carryforward, Amount" } } }, "auth_ref": [] }, "us-gaap_TaxCreditCarryforwardAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxCreditCarryforwardAxis", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Tax Credit Carryforward [Axis]" } } }, "auth_ref": [] }, "antx_TaxCreditCarryforwardExpirationYear": { "xbrltype": "gYearItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "TaxCreditCarryforwardExpirationYear", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax credit carryforward, expiration year", "label": "Tax Credit Carryforward, Expiration Year", "documentation": "Tax credit carryforward, expiration year" } } }, "auth_ref": [] }, "us-gaap_TaxCreditCarryforwardNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxCreditCarryforwardNameDomain", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Tax Credit Carryforward, Name [Domain]" } } }, "auth_ref": [] }, "us-gaap_TemporaryEquitySharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquitySharesOutstanding", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Temporary Equity, Shares Outstanding", "periodEndLabel": "Redeemable convertible preferred stock, ending balance, shares", "periodStartLabel": "Redeemable convertible preferred stock, beginning balance, shares", "terseLabel": "Temporary equity, shares outstanding", "verboseLabel": "Redeemable convertible preferred stock outstanding" } } }, "auth_ref": [] }, "us-gaap_TemporaryEquityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquityTableTextBlock", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityTables" ], "lang": { "en-us": { "role": { "label": "Temporary Equity [Table Text Block]", "terseLabel": "Schedule of Redeemable Convertible Preferred Stock" } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualAxis", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityIncentivePlanAndStockbasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "auth_ref": [] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityIncentivePlanAndStockbasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Domain]" } } }, "auth_ref": [] }, "antx_TotalAdditionalInvestment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "TotalAdditionalInvestment", "crdr": "debit", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Total additional investment.", "label": "Total Additional Investment", "terseLabel": "Total additional investment" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r44" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": [ "r51" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "auth_ref": [ "r72" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": [ "r74" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsFairValueMeasurementOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Financial Instruments [Domain]" } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": [ "r75" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": [ "r76" ] }, "antx_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "TrdArrExpirationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "documentation": "Trd arr expiration date.", "label": "Trd Arr Expiration Date" } } }, "auth_ref": [] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r74" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": [ "r74" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": [ "r77" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": [ "r75" ] }, "antx_TwoThousandSeventeenEquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "TwoThousandSeventeenEquityIncentivePlanMember", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityIncentivePlanAndStockbasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Two thousand seventeen equity incentive plan.", "label": "Two Thousand Seventeen Equity Incentive Plan [Member]", "terseLabel": "2017 Equity Incentive Plan" } } }, "auth_ref": [] }, "antx_TwoThousandTwentyTwoEmployeeStockPurchasePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "TwoThousandTwentyTwoEmployeeStockPurchasePlanMember", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityIncentivePlanAndStockbasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "ESPP, Authorized for Future Issuance", "terseLabel": "2022 Employee Stock Purchase Plan", "label": "Two Thousand Twenty Two Employee Stock Purchase Plan [Member]", "documentation": "Two Thousand Twenty Two Employee Stock Purchase Plan [Member]" } } }, "auth_ref": [] }, "antx_TwoThousandTwentyTwoEquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "TwoThousandTwentyTwoEquityIncentivePlanMember", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityIncentivePlanAndStockbasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Two thousand twenty two equity incentive plan.", "label": "Two Thousand Twenty Two Equity Incentive Plan [Member]", "terseLabel": "2022 Equity Incentive Plan" } } }, "auth_ref": [] }, "us-gaap_TypeOfAdoptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfAdoptionMember", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Accounting Standards Update [Domain]" } } }, "auth_ref": [] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfArrangementAxis", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails", "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityAdditionalInformationDetails", "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "auth_ref": [] }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "USGovernmentAgenciesDebtSecuritiesMember", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsFairValueMeasurementOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "US Government Agencies Debt Securities [Member]", "terseLabel": "U.S. Government Agency Securities" } } }, "auth_ref": [] }, "us-gaap_USTreasurySecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "USTreasurySecuritiesMember", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsFairValueMeasurementOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "US Treasury Securities [Member]", "terseLabel": "U.S. Treasury Securities" } } }, "auth_ref": [] }, "antx_UnderwritingAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "UnderwritingAgreementMember", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityAdditionalInformationDetails", "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Underwriting agreement.", "label": "Underwriting Agreement [Member]", "terseLabel": "Underwriting Agreement" } } }, "auth_ref": [] }, "antx_UnderwritingDiscountsAndCommissions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "UnderwritingDiscountsAndCommissions", "crdr": "debit", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "underwriting discounts and commissions.", "label": "Underwriting Discounts and Commissions", "terseLabel": "Underwriting discounts and commissions" } } }, "auth_ref": [] }, "antx_UnderwrittenOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "UnderwrittenOfferingMember", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityAdditionalInformationDetails", "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Underwritten offering.", "label": "Underwritten Offering [Member]", "terseLabel": "Underwritten Offering" } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": [ "r71" ] }, "antx_UniversityGeorgiaResearchFoundationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "UniversityGeorgiaResearchFoundationMember", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "University Georgia Research Foundation [Member]", "label": "University Georgia Research Foundation [Member]", "terseLabel": "UGARF" } } }, "auth_ref": [] }, "antx_UniversityOfGeorgiaResearchFoundationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "UniversityOfGeorgiaResearchFoundationMember", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureFundingArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "University of georgia research foundation.", "label": "University of Georgia Research Foundation [Member]", "terseLabel": "UGARF Grant" } } }, "auth_ref": [] }, "us-gaap_UnrecognizedTaxBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefits", "crdr": "credit", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails", "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfBeginningAndEndingAmountOfUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Balance at end of year", "periodStartLabel": "Balance at beginning of year", "terseLabel": "Unrecognized tax benefits", "label": "Unrecognized Tax Benefits" } } }, "auth_ref": [] }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "crdr": "credit", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued interest and penalties", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued", "totalLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total" } } }, "auth_ref": [] }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "crdr": "credit", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfBeginningAndEndingAmountOfUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additions related to current year positions", "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions" } } }, "auth_ref": [] }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions", "crdr": "credit", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfBeginningAndEndingAmountOfUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additions related to prior year positions", "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions" } } }, "auth_ref": [] }, "antx_UpfrontPaymentReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://www.an2therapeutics.com/20231231", "localname": "UpfrontPaymentReceived", "crdr": "debit", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Upfront payment received.", "label": "Upfront Payment Received", "terseLabel": "Upfront payment received" } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "auth_ref": [] }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "crdr": "credit", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase in valuation allowance", "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount" } } }, "auth_ref": [] }, "us-gaap_VariableLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableLeaseCost", "crdr": "debit", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfTotalLeaseExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Variable Lease, Cost", "terseLabel": "Variable lease expense" } } }, "auth_ref": [] }, "us-gaap_VestingAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VestingAxis", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityIncentivePlanAndStockbasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Vesting [Axis]" } } }, "auth_ref": [] }, "us-gaap_VestingDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VestingDomain", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureEquityIncentivePlanAndStockbasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Vesting [Domain]" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureNetLossPerShareSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted-average number of shares used in computing net loss per share, diluted", "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total", "verboseLabel": "Weighted-average common shares outstanding used to calculate net loss per share attributable to common stockholders, diluted" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureNetLossPerShareSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Denominator:" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://www.an2therapeutics.com/20231231/taxonomy/role/DisclosureNetLossPerShareSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted-average number of shares used in computing net loss per share, basic", "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total", "verboseLabel": "Weighted-average common shares outstanding used to calculate net loss per share attributable to common stockholders, basic" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii", "Section": "6" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r20": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r21": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r22": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r23": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r24": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r25": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r26": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r27": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r28": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r29": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r30": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r31": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r32": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r33": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r34": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r35": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r36": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r37": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r38": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r39": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r40": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r41": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r42": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r43": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r44": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r45": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r46": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r47": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r48": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r49": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r50": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r51": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r52": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r53": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r54": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r55": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r56": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r57": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r58": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r59": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r60": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r61": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r62": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r63": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r64": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r65": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r66": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r67": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r68": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r69": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r70": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r71": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r72": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r73": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r74": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r75": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r76": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r77": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r78": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r79": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r80": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r81": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } }